Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 11, November, p. 1571–1575

doi: 10.17219/acem/104551

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease

Magdalena Maciorkowska1,A,B,C,D, Dominika Musiałowska1,B,C, Jolanta Małyszko2,E,F

1 Second Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Bialystok, Poland

2 Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Poland

Abstract

Despite great advances in medicine, the proper treatment of arterial hypertension (AH), diabetes mellitus (DM) and chronic kidney disease (CKD) remains a major challenge. Untreated, undiagnosed AH or DM may lead to the development of CKD and consequently to the occurrence of cardiovascular events. Adropin and irisin are newly discovered proteins which may play a role in the development and progression of the chronic diseases mentioned above. Endothelium dysfunction could be a bonding point. The following review paper focuses on adropin and irisin concentrations and their correlations in AH, DM and CKD. Lower adropin concentrations have been measured in patients with primary AH when compared to healthy volunteers. Irisin has reduced blood pressure on nitric oxide (NO)-dependent pathways in experimental studies; a negative correlation between irisin and blood pressure values has also been observed in preeclamptic women. Irisin also plays a role in insulin sensitivity and metabolic disorders. Lower irisin levels have been observed in patients with DM type 2 in comparison to a nondiabetic control group. It is also lower in the serum of pregnant women with gestational DM. A negative correlation between irisin and estimated glomerular filtration rate (EGFR) has also been noted. Adropin and irisin are newly described myokines measured in human plasma in healthy and disease status. Their exact function has not been specified yet and requires further studies.

Key words

diabetes mellitus, hypertension, kidney, proteins

References (52)

  1. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281(14):1291–1297.
  2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913.
  3. Kalaitzidis RG, Bakris GL. Prehypertension: Is it relevant for nephrologists? Kidney Int. 2010;77(3):194–200.
  4. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: A systematic review. J Hypertens. 2004;22(1):11–19.
  5. James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
  6. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132–140.
  7. Brandes RP. Endothelial dysfunction and hypertension. Hypertension. 2014;64(5):924–928.
  8. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468–481.
  9. Marczuk N, Cecerska-Heryć E, Jesionowska A, Dołęgowska B. Adropina – rola fizjologiczna i patofizjologiczna. Postepy Hig Med Dosw. 2016;70:981–988.
  10. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–468.
  11. Huh JH, Ahn SV, Choi JH, Koh SB, Chung CH. High serum irisin level as an independent predictor of diabetes mellitus: A longitudinal population-based study. Medicine (Baltimore). 2016;95(23):e3742.
  12. Desir GV, Peixoto AJ. Renalase in hypertension and kidney disease. Nephrol Dial Transplant. 2014;29(1):22–28.
  13. Redwood H. Hypertension, society, and public policy. Eur Heart J Suppl. 2007;9(Suppl B):B13–B18.
  14. Altincik A, Sayin O. Evaluation of the relationship between serum adropin levels and blood pressure in obese children. J Pediatr Endocrinol Metab. 2015;28(9–10):1095–1195.
  15. Gu X, Li H, Zhu X, et al. Inverse correlation between plasma adropin and ET-1 levels in essential hypertension: A cross-sectional study. Medicine (Baltimore). 2015;90(40):e1712.
  16. Gulen B, Eken C, Kucukdagli OT, et al. Adropin levels and target organ damage secondary to high blood pressure in the ED. Am J Emerg Med. 2016;34(11):2061–2064.
  17. Fu J, Han Y, Wang J, et al. Irisin lowers blood pressure by improvement of endothelial dysfunction via AMPK‐Akt‐eNOS‐NO pathway in the spontaneously hypertensive rat. J Am Heart Assoc. 2016;5(11).
  18. Zhang LJ, Xie Q, Tang CS, Zhang AH. Expressions of irisin and urotensin II and their relationships with blood pressure in patients with preeclampsia. Clin Exp Hypertens. 2017;39(5):460–467.
  19. Zhang W, Chang L, Zhang C, et al. Central and peripheral irisin differentially regulate blood pressure. Cardiovasc Drugs Ther. 2015;29(2):121–127.
  20. Rahmouni K, Morgan DA. Hypothalamic arcuate nucleus mediates the sympathetic and arterial pressure responses to leptin. Hypertension. 2007;49:647–652.
  21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(1):62–69.
  22. Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013;100(1):96–101.
  23. Shoukry A, Shalaby SM, El-Arabi Bdeer S, Mahmoud AA, Mousa MM, Khalifa A. Circulating serum irisin levels in obesity and type 2 diabetes mellitus. IUBMB Life. 2016;68(7):544–556.
  24. Zhang C, Ding Z, Lv G, Li J, Zhou P, Zhang J. Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis. J Diabetes. 2016;8(1):56–62.
  25. Yuksel MA, Oncul M, Tuten A, et al. Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. Diabetes Res Clin Pract. 2014;104(1):171–175.
  26. Celik E, Yilmaz E, Celik O, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med. 2013;41(4):375–380.
  27. Beigi A, Shirzad N, Nikpour F, Nasli Esfahani E, Emamgholipour S, Bandarian F. Association between serum adropin levels and gestational diabetes mellitus: A case-control study. Gynecol Endocrinol. 2015;31(12):939–941.
  28. Dąbrowski FA, Jarmużek P, Gondek A, Cudnoch-Jędrzejewska A, Bomba-Opoń D, Wielgoś M. First and third trimester serum concentrations of adropin and copeptin in gestational diabetes mellitus and normal pregnancy. Ginekol Pol. 2016;87(9):629–634.
  29. Aydin S, Kuloglu T, Aydin S. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides. 2013;47:66–70.
  30. Liu JJ, Liu S, Wong MD, et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complications. 2014;28(2):208–213.
  31. Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013;27(4):365–369.
  32. Zhu D, Wang H, Zhang J, et al. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol. 2015;87:138–147.
  33. Xiang L, Xiang G, Yue L, Zhang J, Zhao L. Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis. 2014;235(2):328–333.
  34. Xiong XQ, Chen D, Sun HJ, et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim Biophys Acta. 2015;1852(9):1867–1875.
  35. So WY, Leung PS. Irisin ameliorates hepatic metabolism and survival in insulin-resistant human HepG2 cells through AMP-activated protein kinase signaling. Int J Biochem Cell. 2016;78:237–247.
  36. Löffler D, Müller U, Scheuermann K, et al. Serum irisin levels are regulated by acute strenuous exercise. J Clin Endocrinol Metab. 2015;100(4):1289–1299.
  37. Peter PR, Park KH, Huh JY, Wedick NM, Mantzoros CS. Circulating irisin levels are not affected by coffee intake: A randomized controlled trial. PLoS One. 2014;9(4):e94463.
  38. Qiu S, Cai X, Yin H, et al. Association between circulating irisin and insulin resistance in non-diabetic adults: A meta-analysis. Metabolism. 2016;65(6):825–834.
  39. Aydin S, Kuloglu T, Aydin S, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem. 2013;380(1–2):73–81.
  40. Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med. 2013;61(8):1161–1164.
  41. Wu L, Fang J, Chen L, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52(5):751–758.
  42. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives. A position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247–259.
  43. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165–180.
  44. Yang S, Xiao F, Pan L, et al. Association of serum irisin and body composition with chronic kidney disease in obese Chinese adults: A cross-sectional study. BMC Nephrol. 2015;16:16.
  45. Rodríguez-Carmona A, Pérez Fontán M, Sangiao Alvarellos S, et al. Serum levels of the adipomyokine irisin in patients with chronic kidney disease. Nefrologia. 2016;36(5):496–502.
  46. Moraes C, Leal VO, Marinho SM, et al. Resistance exercise training does not affect plasma irisin levels of hemodialysis patients. Horm Metab Res. 2013;45(12):900–904.
  47. Lee MJ, Lee SA, Nam BY, et al. Irisin, a novel myokine, is an independent predictor for sarcopenia and carotid atherosclerosis in dialysis patients. Atherosclerosis. 2015;242(2):476–482.
  48. Holzer M, Birner-Gruenberger R, Stojakovic T, et al. Uremia alters HDL composition and function. J Am Soc Nephrol. 2011;22(9):1631–1641.
  49. Wen MS, Wang CY, Lin SL, Hung KC. Decrease in irisin in patients with chronic kidney disease. PLoS One. 2013;8(5):e64025.
  50. Hu W, Chen L. Association of serum adropin concentrations with diabetic nephropathy. Mediators Inflamm. 2016;2016:6038261.
  51. Akcilar R, Kocak FE, Simsek H, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy. 2016;117(2):100–105.
  52. Grzegorzewska A, Niepolski L, Mostowska A, Warchoł W, Jagodziński P. Involvement of adropin and adropin-associated genes in metabolic abnormalities of hemodialysis patients. Life Sci. 2016;160:41–46.
© Wroclaw Medical University